Literature DB >> 47842

Epstein-Barr virus-induced transformation of human leukocytes after cell fractionation.

U Schneider, H zur Hausen.   

Abstract

The efficiency of transformation of human lymphocytes after infection with Epstein-Barr virus (EBV) was determined in fractionated and non-fractionated preparations derived from 16 human cord blood samples and two blood samples from adult donors. The transformation efficiency of macrophage-depleted leukocytes was consistently lower as compared to non-fractionated leukocytes. Additional depletion of B-cells resulted in a further decrease. Reduction of T-cells, however, did not influence significantly the transformation rate. In non-fractionated leukocyte cultures, as well as in macrophage-depleted and B-cell enriched cultures, colonies of transformed cells were regularly observed within the first week of cultivation. All cell lines established after EBV-infection revealed membrane-bound immunoglobulin. Reconstruction of macrophages-depleted, B-cell enriched or B-cell depleted cultures with autologous macrophages resulted in an increase of the transfromation efficiency up to the values of non-fractionated leukocyte preparations. Addition of heterologous human embryonic lung fibroblasts resulted in a similar increase. The results support the interpretation that EBV transforms only those cells of the hematopoetic system which are derived from the bone-marrow entity. The transformation efficiency is considerably increased by co-cultivation of lymphocytes with macrophages and heterologous human fibroblasts which seem to excert a feeder-layer effect by enhancing survival of lymphocytes in vitro.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 47842     DOI: 10.1002/ijc.2910150108

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  21 in total

1.  Cell cycle dependency of a T-cell marker on lymphoblasts.

Authors:  H U Schwenk; U Schneider
Journal:  Blut       Date:  1975-11

2.  Surface markers and size of lymphocytes in human umbilical cord blood stimulated into deoxyribonucleic acid synthesis by Epstein-Barr Virus.

Authors:  J Robinson; A Frank; E Henderson; J Schweitzer; G Miller
Journal:  Infect Immun       Date:  1979-10       Impact factor: 3.441

3.  Heterogeneity of Epstein-Barr virus. III. Comparison of a transforming and a nontransforming virus by partial denaturation mapping of their DNAs.

Authors:  H Delius; G W Bornkamm
Journal:  J Virol       Date:  1978-07       Impact factor: 5.103

4.  Infectious mononucleosis and mononucleosis syndromes.

Authors:  M Fiala; D C Heiner; J A Turner; B Rosenbloom; L B Guze
Journal:  West J Med       Date:  1977-06

5.  Inhibition of the in vitro outgrowth of Epstein-Barr virus-transformed lymphocytes by thymus-dependent lymphocytes from infectious mononucleosis patients.

Authors:  A B Rickinson; D Crawford; M A Epstein
Journal:  Clin Exp Immunol       Date:  1977-04       Impact factor: 4.330

6.  Blastogenic response of purified human T-lymphocyte populations to Epstein-Barr virus (EBV).

Authors:  P Gergely; I Ernberg; G Klein; M Steinitz
Journal:  Clin Exp Immunol       Date:  1977-12       Impact factor: 4.330

7.  Inhibition of EB virus transformation of non-adherent human lymphocytes by co-cultivation with adult fibroblasts.

Authors:  D J Moss; J H Pope; W Scott
Journal:  Med Microbiol Immunol       Date:  1976-12-01       Impact factor: 3.402

8.  [Isoenzyme pattern of acid phosphatase in epstein-barr-virus-DNA positive permanent growing lymphoid cell lines (author's transl)].

Authors:  H W Heyden; R Weber; H Stuckstedte; J G Saal; K O Fresen
Journal:  Blut       Date:  1977-11-22

9.  Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells.

Authors:  K P Mann; D Staunton; D A Thorley-Lawson
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

10.  A routine method for the establishment of permanent growing lymphoblastoid cell lines.

Authors:  H Neitzel
Journal:  Hum Genet       Date:  1986-08       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.